Blood Advances

Article	Citations
Smith CC, Levis MJ, Perl AE, et al. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144-2155.	216
Abramson JS, Siddiqi T, Garcia J, et al. Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel–treated patients in the TRANSCEND NHL 001 trial. Blood Adv. 2021;5(6)	157
Steroid tapering after GVHD Rx: not too fast, not too slow	156
Genome editing of patient-derived iPSCs identifies a deep intronic variant causing aberrant splicing in hemophilia A	145
Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study	142
Addressing and overcoming disparities in GVHD	127
Conditioning intensity and probability of live birth after blood or marrow transplantation, a BMTSS report	125
Predictors of liver disease outcomes in individuals with hemophilia and HCV infection	122
On a collision course: SARS-CoV-2 variants and CAR T cells	119
Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703	108
A mouse model for hemoglobin SC disease recapitulates characteristic human pathologies	107
Infections and parameters of humoral immunity with talquetamab in relapsed/refractory multiple myeloma in MonumenTAL-1	107
Converting IMPROVE bleeding and VTE risk assessment models into a fast-and-frugal decision tree for optimal hospital VTE prophylaxis	101
Campbell BA, Dobos G, Haider Z, et al. International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies. Blood Adv. 2023;7(21):	99
Kennedy VE, Wong C, Huang C-Y, et al. Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma. Blood Adv. 2021;5(23):5344-5348.	97
Pirillo C, Birch F, Tissot FS, et al. Metalloproteinase inhibition reduces AML growth, prevents stem cell loss, and improves chemotherapy effectiveness. Blood Adv. 2022;6(10):3126-3141.	97
Priapism Before and After Hematopoietic Stem Cell Therapy in Individuals with Sickle Cell Disease	95
Complement C5 inhibition in early onset HELLP syndrome	92
LMWH prevents thromboinflammation in the placenta via HBEGF-AKT signaling	91
ASCT vs CART for patients with relapsed LBCL in PR: role of TMTV	91
Complete absence of GLUT1 does not impair human terminal erythroid differentiation	90
Pirfenidone for the treatment of bronchiolitis obliterans syndrome related to chronic graft-versus-host disease	86
COVID-19 vaccination during therapy in relation to COVID-19 death in CLL	82
Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial	82
Glucagon-like peptide 1 receptor agonists and venous thromboembolism in type 2 diabetes: a target trial emulation	81

Improvements in Health-Related Quality of Life in Patients with Transfusion-Dependent β-Thalassemia After Exagamglogene Autotemcel	81
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML	79
Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia	79
Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium	77
Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell–mediated tumor responses	74
Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi	70
Cortisol in sickle cell disease: a systematic review and meta-analysis	69
Characteristics and outcomes of patients with CLL and CDKN2A/B deletion by fluorescence in situ hybridization	69
The A-HIPI prediction model in advanced-stage Hodgkin lymphoma: identification of risk groups and creation of an online tool	68
Ibrutinib plus rituximab vs ibrutinib monotherapy in patients with Waldenström macroglobulinemia: a pooled analysis	68
Genome-wide whole-blood transcriptome profiling across inherited bone marrow failure subtypes	68
Outcomes with Third Party Virus Specific T-cells After the Use of Single Antigen Cell Lines to Predict HLA Restriction	67
Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years	67
Transfusion therapy for sickle cell disease: what’s new?	65
Bite-size introduction to canine hematologic malignancies	65
BCL11A promotes myeloid leukemogenesis by repressing PU.1 target genes	65
Best but not perfect: indirect measure of low iron stores	63
ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis	63
Selective modulation of activated protein C activities by a nonactive site–targeting nanobody library	63
Desensitization to calaspargase pegol appears to be less successful than pegaspargase	63
Deep PIM kinase substrate profiling reveals new rational cotherapeutic strategies for acute myeloid leukemia	62
Applying CRISPR-Cas9 screens to dissect hematological malignancies	61
Reduced FVIII recovery associated with anti-FVIII PEG antibodies after BNT162b2 SARS-CoV-2 vaccination	61
Structural analysis of platelet fragments and extracellular vesicles produced by apheresis platelets during storage	61
Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia	61
A novel 3D culture model recapitulates primary FL B-cell features and promotes their survival	59
Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia	59
Longitudinal clinical data improve survival prediction after hematopoietic cell transplantation using machine learning	59
Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea	59
Megakaryocyte/platelet-derived TGF-β1 inhibits megakaryopoiesis in bone marrow by regulating thrombopoietin production in liver	59
Matrix stiffness controls megakaryocyte adhesion, fibronectin fibrillogenesis, and proplatelet formation through Itgβ3	59
Genetic landscapes and curative effect of CAR T-cell immunotherapy in patients with relapsed or refractory DLBCL	59
Pediatric adapted risk index to predict 2-year transplant-related mortality post-HSCT in children	58
Targeting bone marrow mesenchymal stromal cell–derived IL-6 to overcome acute myeloid leukemia chemoresistance	57
Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry	57
International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies	57
Mitigating T-cell mitochondrial dysfunction in CLL to augment CAR T-cell therapy: evaluation in an immunocompetent model	57
Molecular subclusters of follicular lymphoma: a report from the United Kingdom’s Haematological Malignancy Research Network	57
The OHI index predicts early mortality from organ dysfunction and survival benefit from etoposide in patients with lymphoma	57
Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel	56
CD58 loss in tumor cells confers functional impairment of CAR T cells	56
Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes	56
Sickle cell disease is a risk factor for transplant-associated thrombotic microangiopathy in children	56
American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients	55
Long-term survival with sickle cell disease: a nationwide cohort study of Medicare and Medicaid beneficiaries	55
Deletion of Y chromosome before allogeneic hematopoietic stem cell transplantation in male recipients with female donors	55
Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B-cell malignancies	54
Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia	54
Chimeric antigen receptor T-cell therapy in adults with B-cell acute lymphoblastic leukemia	53
Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma	52

Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trial	52
Efficacy and safety of BCMA nanobody CAR T-cell therapy in relapsed or refractory plasma cell myeloma	51
Implementation of hospital-based sickle cell newborn screening and follow-up programs in Haiti	51
The ISHLT chronic lung allograft dysfunction consensus criteria are applicable to pulmonary chronic graft-versus-host disease	51
Tumor microenvironment differences between diagnostic and relapsed classic Hodgkin lymphoma revealed by scRNA-seq	51
Long-term data needed for SCD gene therapy	51
Can baseline cytomegalovirus IgG titers predict cytomegalovirus reactivation after ide-cel therapy?	51
Opposing effects of KDM6A and JDP2 on glucocorticoid sensitivity in T-ALL	51
Association between hemoglobin values and VWF assays: a multicenter investigation	51
Interpretation of response in BOS: the definitions remain key	50
High pulmonary hypertension risk by echocardiogram shortens survival in polycythemia vera	50
Neighborhood Socioeconomic Status and Overall Survival among Children with Acute Lymphoblastic Leukemia	50
Another step toward frontline BTK inhibitor therapy in MCL	49
Epigenetic features support the diagnosis of B-cell prolymphocytic leukemia and identify 2 clinicobiological subtypes	49
FBXW7β isoform drives transcriptional activation of the proinflammatory TNF cluster in human pro-B cells	49
Evaluating complement dysregulation in livedoid vasculopathy using a functional assay	49
G3BP2-KIT drives leukemia amenable to kinase inhibition in Ph-like ALL	49
Code status transitions in patients with high-risk acute myeloid leukemia	48
Mitochondrial dsRNA from B-ALL cells stimulates mesenchymal stromal cells to become cancer-associated fibroblasts	48
Return emergency department visits for recurrent pulmonary embolism symptoms in children and adolescents	48
Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities	47
Myb drives B-cell neoplasms and myeloid malignancies in vivo	47
Horwitz SM, Scarisbrick JJ, Dummer R, et al. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician’s choice in cutaneous T-cell lymphoma: final data. Blood Adv. 2021;5(23):5098-5	47
Severe Parvovirus B19 Infection in Patients with Sickle Cell Disease Hospitalized in Intensive Care Unit	47
Hasselbalch HC, Kristiansen MH, Kjær L, et al. CHIP-JAK2V617F, chronic inflammation, abnormal megakaryocyte morphology, organ failure, and multimorbidities. Blood Adv. 2024;8(3):681-682.	47
Distinguishing STAT3/STAT5B-mutated large granular lymphocyte leukemia from myeloid neoplasms by genetic profiling	47
An αIIbβ3 ligand-mimetic murine monoclonal antibody that produces platelet activation by engaging the FcγIIa receptor	47
Antileukemic properties of the kinase inhibitor OTSSP167 in T-cell acute lymphoblastic leukemia	46
Donor age contributes more to the rheological properties of stored red blood cells than donor sex and biological age distribution	46
Sustained hematologic remission after discontinuation of sutimlimab treatment in patients with cold agglutinin disease	46
Uptake of long-chain fatty acids from the bone marrow suppresses CD8+ T-cell metabolism and function in multiple myeloma	46
EMD originates from hyaluronan-induced homophilic interactions of CD44 variant-expressing MM cells under shear stress	46
Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis	46
A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease	46
Dasatinib-induced spleen contraction leads to transient lymphocytosis	45
Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease	45
Outcomes following transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from ASPEN	45
Adaptation of Serious Illness Care Program to be delivered via telehealth for older patients with hematologic malignancy	45
Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia	44
Impaired exercise capacity in post–COVID-19 syndrome: the role of VWF-ADAMTS13 axis	44
High frequency of central nervous system involvement in transformed Waldenström macroglobulinemia	44
Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma	44
U2AF1 and EZH2 mutations are associated with nonimmune hemolytic anemia in myelodysplastic syndromes	44
Cabozantinib and thromboembolism in patients with cancer: a systematic review, meta-analysis and retrospective study	44
T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a phase 1 trial	44
Cumulative donor-specific antibody threshold predicts platelet transfusion response in HLA-alloimmunized patients	44
PD-1 inhibition for relapse after allogeneic transplantation in acute myeloid leukemia and myelodysplastic syndrome	43
Graft-versus-host disease may cause pulmonary restriction, but not all restriction is graft-versus-host disease	43
Ibrutinib increases miR-181a/b in leukemic cells from patients with chronic lymphocytic leukemia	43
Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma	43
Danazol treatment for telomere biology disorders: long-term results of a phase I/II study	43
Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS	43
Longitudinal analysis of cardiac abnormalities in pediatric patients with sickle cell anemia and effect of hydroxyurea therapy	43
Fanconi anemia neuroinflammatory syndrome: brain lesions and neurologic injury in Fanconi anemia	43
Transcriptomic analysis reveals proinflammatory signatures associated with acute myeloid leukemia progression	42
Mutant PIK3CA is a targetable driver alteration in histiocytic neoplasms	42
CAR T-cell therapy for secondary CNS DLBCL	42
D-dimer for patients on VKA vs DOAC: impact on the validity of D-dimer to make decision for extended anticoagulation	42
Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience	42
Genomic landscape of patients with germline RUNX1 variants and familial platelet disorder with myeloid malignancy	41
Trends in volumes and survival after hematopoietic cell transplantation in racial/ethnic minorities	41
AMPK drives both glycolytic and oxidative metabolism in murine and human T cells during graft-versus-host disease	41
Commentary on the ASH ISTH NHF WFH 2021 guidelines on the diagnosis of VWD: reflections based on recent contemporary test data	41
Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST study	41
Establishment of a predictive model for GVHD-free, relapse-free survival after allogeneic HSCT using ensemble learning	41
Long live the red blood cell: biotin tagging in SCD	40
Deciphering the regulatory landscape of murine splenic response to anemic stress at single-cell resolution	40
RNA-regulatory exosome complex suppresses an apoptotic program to confer erythroid progenitor cell survival in vivo	40
Cleavage of talin by calpain promotes platelet-mediated fibrin clot contraction	40
Bilineal evolution of a U2AF1-mutated clone associated with acquisition of distinct secondary mutations	40
Immune profiling after allogeneic hematopoietic cell transplantation in pediatric acute myeloid leukemia	40
Factor XI inhibitors: a new class of anticoagulants	39
Cutaneous dysbiosis characterizes the post–allogeneic hematopoietic stem cell transplantation period	39
The American Society of Hematology Health Equity Compendium: examining health equity across the Blood journals	39
Bridging therapy before axi-cel for lymphoma	39
Commentary on the 2021 ASH Guidelines on use of anticoagulation in patients with COVID-19 being discharged from the hospital	39
Gioacchino E, Koyunlar C, Zink J, et al. Essential role for Gata2 in modulating lineage output from hematopoietic stem cells in zebrafish. Blood Adv. 2021;5(13):2687-2700.	38
Cytokine receptor IL27RA is an NF-κB–responsive gene involved in CD38 upregulation in multiple myeloma	38
HSCT using carrier donors for CD40L deficiency results in excellent immune function and higher CD40L expression in cTfh	38
Allogeneic hematopoietic stem cell transplantation in germline DDX41 mutated patients with myeloid malignancies	38

Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial	38
Presentation of CXCL12γ by heparan sulfate proteoglycans activates CXCR4 without desensitization in normal and malignant B cells	38
Interactions between integrin α9β1 and VCAM-1 promote neutrophil hyperactivation and mediate poststroke DVT	38
Should we move to a genomic classification of neutrophilic myeloid neoplasms?	38
Comments and concerns on the analysis of DAPS-ITP trial	37
Alliance A061202: ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse	37
Thromboprophylaxis in hospitalized and nonhospitalized medical patients: what’s new?	37
A CD3 humanized mouse model unmasked unique features of T-cell responses to bispecific antibody treatment	37
Efficacy and safety of dapsone in adult primary immune thrombocytopenia	37
Characteristics, primary treatment, and survival of MDS/MPN with neutrophilia: a population-based study	37
Is estimated exposure an accurate surrogate for measured fludarabine levels in patients with CAR T-cell therapy?	37
Evaluation of allogeneic and autologous membrane-bound IL-21–expanded NK cells for chronic lymphocytic leukemia therapy	37
Mass spectrometry-detected MGUS is associated with obesity and other novel modifiable risk factors in a high-risk population	36
JMML tumor cells disrupt normal hematopoietic stem cells by imposing inflammatory stress through overproduction of IL-1β	36
Long-term outcomes of chemoimmunotherapy with obinutuzumab/chlorambucil in chronic lymphocytic leukemia	36
HLA reduction of human T cells facilitates generation of immunologically multicompatible cellular products	35
Cell-free DNA measurable residual disease as a predictor of postallogeneic hematopoietic cell transplant outcomes	35
Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and is associated with high response rates	35
Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912	35
World Coalition on SCD launches, sparking global focus on SCD diagnosis and care	35
Digital pathology in pediatric nodular lymphocyte-predominant Hodgkin lymphoma: correlation with treatment response	35
Prognostic impact of patient-reported symptoms in multiple myeloma	35
Effect of rabbit ATG PK on outcomes after TCR-αβ/CD19–depleted pediatric haploidentical HCT for hematologic malignancy	35
Analysis of immune responses in patients with CLL after heterologous COVID-19 vaccination	35
Population-scale Analysis Reveals Germline Loss of SERPING1 (C1-Inhibitor) is a Polyphenotypic Thrombotic Disorder	35
Low frequency of Vγ9Vδ2 T cells predicts poor survival in newly diagnosed acute myeloid leukemia	35
T-cell malignancies with anti-CD19 chimeric antigen receptor T-cell therapy	35
Cost-effectiveness of Voncento prophylaxis vs on-demand treatment in von Willebrand disease in the United Kingdom	35
Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab	35
Feasibility of high-dose methotrexate administered on day 1 of (R)CHOP in aggressive non-Hodgkin lymphomas	35
Combinatorial targeting of epigenome-modifying enzymes with decitabine and RN-1 synergistically increases HbF	35
Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia	35
Thyroid hormones contribute to JAK/STAT pathway abnormal activation, promoting T-cell lymphoma dissemination	34
Role of race and ethnicity in survival among children/young adults with relapsed ALL: a Children's Oncology Group report	34
Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Follicular Lymphoma: Phase 1/2 BRUIN Study	34
To pursue gene therapy or not? Is it feasible after graft failure in allogeneic hematopoietic cell transplant recipients	34
Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study	34
Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma	34
Molecular profiling of primary renal diffuse large B-cell lymphoma unravels a proclivity for immune-privileged tropism	34
KDIGO-Defined Kidney Dysfunction Predicts Long-Term Outcomes in a Multi-Center Cohort of Adults with Sickle Cell Disease	34
Safety and efficacy of letetresgene autoleucel alone or with pembrolizumab for relapsed/refractory multiple myeloma	34
Cellular and biochemical heterogeneity contributes to the phenotypic diversity of transfusion-dependent β-thalassemia	33
The use of FDA-approved medications for preventing vaso-occlusive events in sickle cell disease	33
Familial Clusters and Clinical Features, Complications, and Outcomes in 1000 Patients with Waldenström Macroglobulinemia	33
IgG testing, immunoglobulin replacement therapy, and infection outcomes in patients with CLL or NHL: real-world evidence	33
TP53-mutant myelodysplastic syndrome and acute myeloid leukemia: the black hole of hematology	33
Dual ASXL1 and CSF3R mutations drive myeloid-biased stem cell expansion and enhance neutrophil differentiation	33
Risk of infectious adverse events of venetoclax therapy for hematologic malignancies: a systematic review and meta-analysis of RCTs	33
Response to Danilov et al	33
Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy	33
Early response markers predict survival after etoposide-based therapy of hemophagocytic lymphohistiocytosis	33
Lineage switching of the cellular distribution of BRAF V600E in multisystem Langerhans cell histiocytosis	33
Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group	33
A 69 long noncoding RNA signature predicts relapse and acts as independent prognostic factor in pediatric AML	33
International consensus statement on the management of cardiovascular risk of Bruton’s tyrosine kinase inhibitors in CLL	33
Patient-specific MDS-RS iPSCs define the mis-spliced transcript repertoire and chromatin landscape of SF3B1-mutant HSPCs	32
Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study	32
Tumor-associated antigen–specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphoma	32
Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy	32
Orthopedic toxicities among adolescents and young adults treated in DFCI ALL Consortium Trials	32
Daratumumab for immune thrombotic thrombocytopenic purpura	32
Pilot study of an inpatient physical activity intervention for older adults treated intensively for acute myeloid leukemia	32
PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma	32
Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma	32
Effectiveness and safety of prophylactic anticoagulation among hospitalized patients with inflammatory bowel disease	32
Eculizumab for refractory thrombosis in antiphospholipid syndrome	32
Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma	32
Expanding donor options: haploidentical transplant recipients are also highly likely to have a 7/8-matched unrelated donor	32
Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial	32
Genetically defined individual reference ranges for tryptase limit unnecessary procedures and unmask myeloid neoplasms	31
Clinical features, pathophysiology, and therapy of poor graft function post–allogeneic stem cell transplantation	31
Outcomes in children with provoked venous thrombosis and antiphospholipid antibodies: findings from the Kids-DOTT trial	31
Transcriptomic atlas reveals organ-specific disease tolerance in sickle cell mice	31
Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation	31
Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E–positive LCH	31
Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD	31
Racial and socioeconomic status diversity and GVHD outcomes	31
CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy	31
Utility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53-mutated MDS/AML	31
Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma	31
Tarlock K, Gerbing RB, Ries RE, et al. Prognostic impact of cooccurring mutations in FLT3-ITD pediatric acute myeloid leukemia. Blood Adv. 2024;8(9):2094-2103.	31
Molecular profiling of primary renal marginal zone lymphoma reveals overlapping features with extranodal marginal zone lymphoma	30
Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes	30
Histiocytosis of the orbit and its association with KRAS mutations	30
Autologous stem cell transplantation in T-cell/histiocyte-rich large B-cell lymphoma: EBMT Lymphoma Working Party study	30
USP7 alterations are associated with a poor survival in pediatric T-cell Acute Lymphoblastic Leukemia	30
Synonymous ADAMTS13 variants impact molecular characteristics and contribute to variability in active protein abundance	30
Peripheral neuropathy and BTKis in Waldenström: a response?	30
Implementing ASH’s guidelines for acute medical care for incarcerated children and adults with sickle cell disease	30
Comparison of bone marrow and peripheral blood aberrant plasma cell assessment by NGF in patients with MM	30
Lissitchkov T, Willemze A, Katragadda S, et al. Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study. Blood Adv. 2022;6(4):1089-1094.	30
Characterization and treatment outcomes of malignant histiocytoses in a retrospective series of 141 cases in France	30
Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL	30
Do sophisticated models give the full picture of allogeneic hematopoietic stem cell transplantation effect?	30
Liver abnormalities are frequent and persistent in patients with Fanconi anemia	30